Prostate cancer treatment with Radium 223 PSMA therapy

Radium-223 PSMA is a unique treatment option for prostate cancer patients with metastases. The radioactive isotope Radium-223 is the principal active ingredient and a powerful alpha emitter. After injection, the substance is directed to the place where the prostate malignancy grows. When radium particles detect a tumor, they disintegrate and destroy the cancer cell with alpha-radiation. It has a small radius, so healthy cells, and bone marrow remain safe. The drug is injected intravenously within minutes. The dose is calculated individually, taking into account the weight of the patient and the time of manufacture of the drug. Radium accumulates rapidly in the metastatic lesions. After 15 minutes, only 20% of the total dose remains in the blood, and 1% after a day. After the injection, doctors monitor the patient's condition for several hours. The treatment is well tolerated. Symptomatic therapy is used in case of diarrhea, nausea, or vomiting. Radium-223 PSMA is well-tolerated and requires no restrictions, such as sleeping in a separate room or minimizing communication with children. Physicians observe prostate cancer shrinking and complete cancer cures in some cases. In some scenarios, doctors might recommend repeated Radium-223 therapy.